T-cell Response – Page 4 – Communicable Diseases Research

A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients

Article

Published on 2022-10-132022-11-15
Journal: Upsala Journal of Medical Sciences [Category] COVID19(2023년), SARS, 진단, 치료기술,

Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis

Article

Published on 2022-10-122022-11-15
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제,

[키워드] addition age anti-CD20 therapy anti-S anti-S antibody anti-SARS-CoV-2 antibodies antibody Antibody Response BNT162b2 cell-mediated response Cellular immune response cellular immune responses ChAdOx1 Concentration Corona covariate adjustment COVID-19 COVID-19 vaccine declined dependent on DMARD (disease-modifying antirheumatic drug treatment) domains dose enrolled Factor healthy controls humoral IL-6 inhibitor immune response Infection inhibited investigated IQR magnitude median time mRNA-1273 Patient patients patients treated peptides positive patient reduced respiratory rheumatoid arthritis RNA RNA vaccine SARS-CoV-2 significant effect significantly Specific specific antibodies specific antibody subject T-cell T-cell Response targeted therapy the healthy the interferon the SARS-CoV-2 the vaccine therapy vaccination Vaccine variables was measured were infected
[DOI] 10.3389/fimmu.2022.960001 PMC 바로가기

Adaptive immunity to SARS-CoV-2 infection: A systematic review

Article

Published on 2022-10-102022-11-15
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 바이오마커,

[키워드] acute respiratory syndrome adaptive Adaptive immunity addressed Alpha Antigen article B cell Biomarker case-control study caused CD4+ T cell CD8+ CD8+ T lymphocytes Cell cell types Characteristics clinical benefits Cohort studies coronavirus coronavirus disease Course COVID-19 Critically ill Critically ill patient cross-sectional CXCL9 Cytokines database disease English Evidence experimental evidence follicular HLA-DR humoral Humoral immunity IL-10 IL-13 IL-15 IL-17 IL-1α IL-2 IL-21 IL-22 IL-23 IL-4 IL-5 IL-7 immune system Immunity immunological Immunological memory immunopathological in vitro assays individuals inflammatory mediator involved leukocyte Ligand lymphocyte marker mild case Necrosis poor prognosis predominant produced programmed cell death progression Protein Regulatory T cell responsible SARS-CoV-2 SARS-COV-2 infection SciELO secretion severity Spanish subpopulation systematic review T helper T helper cell T lymphocyte T-cell Response Tfh TGF-β Th1 Th17 Th2 the antibody the disease TNF-α Treg tumor growth Vaccine variable
[DOI] 10.3389/fimmu.2022.1001198 PMC 바로가기

Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients

Article

Published on 2022-10-062022-11-15
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제,

[키워드] ACE2 binding addition administration analysed anti-RBD B.1 binding BNT162b2 boost immunity cellular Control controls COVID-19 COVID-19 vaccination Decline declining Delta detectable dialysis dose doses group Haemodialysis Haemodialysis patient humoral humoral immune response Humoral immunity IgG IgG response immune immune evasion immune protection immunoassays Immunocompromised individual individuals information interferon γ knowledge longitudinal longitudinal response maintain mixed mRNA vaccination mRNA mRNA vaccination mRNA-1273 mucosal omicron Omicron variant of concern Patient patients Prevent protective immunity RBD reached regimen remained respond poorly restored SARS-CoV-2 vaccination SARS-CoV-2 variant second vaccination severe COVID-19 significantly increased spike subsequent Support T-cell Response tested the receptor-binding domain vaccination Vaccine variant variants of concern
[DOI] 10.3389/fimmu.2022.1004045 PMC 바로가기

Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults

Article

Published on 2022-10-042022-11-16
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종,

[키워드] Activation Adaptive immune response antibodies antibody BCG BCG vaccination benefit booster breadth CD4+ CD8+ T-cell changes changes in chromatin Combination COVID-19 vaccines Delta Effect effector memory eight elevated ENhance Epigenetic Evidence expressing greater Heterologous highlighting IL-1β IL-2 immune response Immunity in-depth analysis India marker memory T-cell response mutant NAb Neutralizing provide revaccination SARS-CoV-2 seronegative significantly higher subset T cell T-cell Response tested TNF-α TNF-α expression trained immunity Tuberculosis vaccination Vaccine vaccine-induced immune response
[DOI] 10.3389/fimmu.2022.985938 PMC 바로가기

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination

Article

Published on 2022-10-042022-11-15
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술,

[키워드] administration Adverse adverse effect anti-RBD Anti-RBD IgG antibody Antibody Response Arm ARMS binding domain BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 comparable Concentration conducted CoronaVac country COVID COVID vaccine COVID-19 COVID-19 vaccine COVID-19 vaccines dose Effect Effects eligible exploratory first dose fractional dose vaccination Frame Heterologous heterologous regimen highest homologous IgG immunogenic implication IMPROVE Intradermal intradermal vaccination intradermal vaccine intramuscular intramuscular vaccination less lowest of BNT162b2 Omicron variant pilot study Population Protein regimen regimens reported Safe Safety SARS-CoV-2 variants second dose spike Standard dose Study participants systemic adverse reaction T-cell Response the SARS-CoV-2 undetectable vaccination Vaccine vaccine immunogenicity vaccine safety
[DOI] 10.3389/fimmu.2022.1010835 PMC 바로가기

Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers

Article

Published on 2022-10-032022-11-15
Journal: Pathogens and disease [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] assays B-cell baseline booster booster vaccines cellular Cellular immune response convalescent convalescent individual Coronavirus-2 determine ELISA ELISPOT ELISpot IFN-γ release assay first dose Health care worker health care workers hospital humoral humoral immune responses Humoral immunity IFN-γ IgG level IgG responses immune individual individuals interferon-γ janssen mounted mRNA mRNA vaccine natural immunity Netherlands occurred offer pandemic Pfizer postvaccination receiving recipient responses SARS-CoV-2 serological seronegative seropositive severe disease spike-specific cellular immunity Support T-cell T-cell Response vaccination Vaccine variants of concern vector vaccine Virus neutralization VNT waned
[DOI] 10.1093/femspd/ftac035 PMC 바로가기

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant

심장 이식 수혜자를 대상으로 6개월 동안 세 번째 BNT162B2 코로나19 백신에 대한 세포 및 체액 반응의 동역학 - 오미크론 변종에 대한 영향

Article

Published on 2022-10-012022-11-15
Journal: The Journal of heart and lung transplantation : th [Category] COVID19(2023년), SARS, 백일해, 변종, 진단, 파상풍,

Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital

Article

Published on 2022-09-232022-11-15
Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술,

Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs

Article

Published on 2022-09-232022-11-15
Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome adverse event antibody concentration axial spondyloarthritis biological disease-modifying drug BNT162b2 BNT162b2 vaccine booster booster doses booster vaccination clinical questionnaire Cohort cohorts comparable coronavirus disease Coronavirus-2 COVID-19 enrolled evaluated Evidence flow cytometric General population healthy control humoral IL-17 immune response Immune-mediated inflammatory disease immunogenicity individuals inhibitor inhibitors intracellular cytokine investigated male no difference outcome Patient patients patients treated peptide-based persistence prospective observational study Responder Safety SARS-CoV-2 Specific spondyloarthritis subgroups T-cell T-cell immune response T-cell Response therapy TNFα treated tumor necrosis factor-alpha vaccination virus-neutralizing antibody were assessed
[DOI] 10.3389/fimmu.2022.1010808 PMC 바로가기